Real world efficacy of 12 weeks sofosbuvir, daclastivir with ribavirin among cirrhotic pre and post-transplant genotype 3 hepatitis C infected patients

Autor:	Ahmed M. Elsharkawy, V. Wood, G.H. Haydon, K. Rye, Chris Corbett, E. Unitt, M. Roberts, I. Perry, D. Schmidt-Martin, S. Singhal, Sally Bufton, S. Eldred, David Mutimer, H. Dillon
Rok vydání:	2017
Předmět:	medicine.medical_specialty Hepatology Sofosbuvir business.industry Ribavirin Hepatitis C medicine.disease Gastroenterology chemistry.chemical_compound chemistry Internal medicine Genotype medicine business Pre and post medicine.drug
Zdroj:	Journal of Hepatology. 66:S301-S302
ISSN:	0168-8278
DOI:	10.1016/s0168-8278(17)30919-4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5fc13741fb38d48bdc509eded88ac688 https://doi.org/10.1016/s0168-8278(17)30919-4 Zobrazit plný text záznamu Full Text from ScienceDirect